Mesoblast stock outlines RYONCIL expansion and pipeline plans
Published on 11/20/2026 at 20:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMesoblast outlines commercial and clinical milestones
- FY2026 net revenue reached US$115 million, while gross profit on total sales excluding amortization was US$110 million.
- The company completed treatment of 350 patients in a Phase 3 chronic low back pain trial, with a readout targeted for the second half of 2027.
- Mesoblast said it had FDA alignment to file for approval of rexlemestrocel-L in an end-stage heart failure indication involving LVAD patients and major gastrointestinal bleeding.
Mesoblast outlined commercial and clinical milestones at the Australian Securities Exchange Investor Day on November 16, 2026. The company described its transition to a commercial-stage biotechnology business, led by RYONCIL sales and development programs for rexlemestrocel-L, according to a SEC filing containing the company presentation.
Commercial growth and financial milestones
The presentation reported US$115 million in FY2026 net revenue in the first full year after the U.S. launch of RYONCIL. Gross profit on total sales, excluding amortization expense, was US$110 million.
Mesoblast also said it had entered into a US$125.0 million five-year non-dilutive credit-line facility. The facility consolidates and retires two higher-cost facilities, supporting commercial expansion and late-stage development.
Clinical programs move toward catalysts
The company completed treatment of 350 patients in a Phase 3 trial for chronic low back pain. The primary readout is targeted for the second half of calendar 2027, followed by a potential Biologics License Application filing.
Mesoblast said its registration trial for extending RYONCIL to adults with steroid-refractory acute graft-versus-host disease had begun enrolling. The trial targets 40 U.S. centers, with an interim analysis expected in the fourth quarter of 2027.
For rexlemestrocel-L, Mesoblast said the FDA had confirmed that a filing may proceed for end-stage heart failure patients with left ventricular assist devices and life-threatening major gastrointestinal bleeding. In the LVAD II study, the presentation reported six-month major mucosal bleeding rates of 15.6 per 100 patient-months for control patients and 3.8 for rexlemestrocel-L among 159 subjects.
Mesoblast stock quote
Mesoblast stock traded at 1.03 euros on Lang & Schwarz at 20:33 CET on Friday, November 20, 2026.
Mesoblast Limited
- Company: Mesoblast Limited
- ISIN: AU000000MSB8
- Listings: Australian Securities Exchange and Nasdaq
- Ticker: MSB on ASX; MESO on Nasdaq
- Quote: 1.03 euros on Lang & Schwarz, November 20, 2026, 20:33 CET
- Sector: Healthcare
- Industry: Biotechnology
The Australian market environment provides the broader setting for ASX-listed healthcare companies.
